Navigation Links
Alexza Reports Preliminary 2013 Second Quarter Financial Results
Date:8/8/2013

MOUNTAIN VIEW, Calif., Aug. 8, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported preliminary financial results for the quarter ended June 30, 2013.  The preliminary net loss for the quarter ended June 30, 2013, was $3.4 million compared to $7.0 million during the same quarter in 2012.  The preliminary net loss for the six months ended June 30, 2013 and 2012, was $24.1 million and $10.8 million, respectively.  At June 30, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $35.0 million.

"Alexza continues to mark steady progress against our objectives to commercialize ADASUVE® and advance our Staccato® pipeline candidates," said Thomas B. King, President and CEO of Alexza.  "In the second quarter, we entered into an exclusive agreement with Teva to market ADASUVE in the U.S.  We believe Teva is an ideal partner for ADASUVE, and we are impressed by their capabilities, commitment and enthusiasm." 

King continued, "Most recently, our partner Ferrer initiated sales of ADASUVE in the European Union, with the first product sale in Germany.  In addition, we are preparing to advance AZ-002 (Staccato alprazolam) for acute repetitive seizures into Phase 2 clinical studies by year-end."

Alexza Business Updates

  • In May 2013, Alexza entered into an exclusive U.S. license and supply agreement for ADASUVE with Teva Pharmaceuticals USA, Inc.  Teva is responsible for all U.S. development and commercialization activities for ADASUVE, including U.S. post-approval clinical studies.  Alexza is responsible for manufacturing and supplying ADASUVE to Teva for commercial sales and clinical trials.
    Alexza received an upfront cash payment of $40 million, $1
    '/>"/>

  • SOURCE Alexza Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
    2. Alexza Reports 2013 First Quarter Financial Results
    3. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
    4. Alexza to Report 2013 First Quarter Financial Results on Thursday, May 9, 2013
    5. Alexza Reports 2012 Fourth Quarter and Full Year Financial Results
    6. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
    7. Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013
    8. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
    9. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
    10. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
    11. Alexza Announces Management Promotions
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Md. , Sept. 30, 2014  Tasly ... way to modernize medicine, announced today the launch ... of nutraceuticals developed to address men and women ... healthy and vibrant into old age while helping ... includes three condition-specific, whole-food and herb-based formulas, namely, ...
    (Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
    (Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
    Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
    ... March 15, 2012  Continuing to meet the complex ... a US-based, ISO13485-certified, FDA compliant contract manufacturing and ... with FDA compliant storage and order fulfillment services ... Telcare,s FDA and HIPAA-compliant solution, ...
    ... 15, 2012 /PRNewswire-Asia-FirstCall/ --  Dehaier Medical Systems Ltd. ... emerging leader in the development, assembly, marketing and ... today announced that the Company plans to release ... full year of 2011 ended December 31, 2011 on Monday, March ...
    Cached Medicine Technology:Cogmedix Provides Medical Device Storage and Order Fulfillment Services for Telcare Medical Supply 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 3
    (Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
    (Date:10/1/2014)... 01, 2014 First Warning Systems, a ... cellular changes throughout the body, announced the company is ... address the company’s breadth of upcoming product releases. The ... screening technology. , “Our initial focus will be an ... detects abnormal circadian cellular changes over time,” said Rob ...
    (Date:10/1/2014)... from Duke Medicine suggests that some people who are ... hard-wired to gain weight when exposed to chronic stress, ... 13 percent of people, all of whom are Caucasian, ... help them reduce heart disease with simple interventions such ... "Genetic susceptibility, psychosocial stress and metabolic factors act in ...
    (Date:10/1/2014)... Inc., announced today their new NoteSwift™ 2.0 for Allscripts ... the bridge between the EHR and Dragon Medical interpreting ... at the point of care. NoteSwift reduces the time ... than half – and virtually eliminates mouse clicks – ... EHR use according to the June 12, 2014 HIMSS ...
    (Date:10/1/2014)... Watsonville, California (PRWEB) October 01, 2014 ... initiative to benefit a very special cause. The ... and support for Paws for Veterans, a nonprofit ... veterans, while also rescuing shelter dogs that would ... purchases of featured products will support monthly donations ...
    Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
    ... Residents forced to,leave their homes and businesses due to flooding ... their belongings. The Restoration Industry,Association (RIA, formerly ASCR) suggests that ... during an evacuation:, -- Health & homeowners ... irreplaceable mementos, disposable camera, digital ...
    ... /PRNewswire/ - Media representatives are invited,to a photo opportunity ... Schwarzenegger, the California Governor, in light of an,international collaboration ... BIO 2008 International Convention in San Diego., ... Health ...
    ... 18, 2008) -- Could injecting a gene into a ... life-threatening condition? Physician-scientists are setting out to answer that ... to treat severe heart failure. , NewYork-Presbyterian Hospital/Columbia ... New York City area where the therapy is currently ...
    ... More Components to Fully Measure Quality, WASHINGTON, ... today commended the Centers for Medicare & Medicaid,Services ... care through,the newly introduced "five-star" rating system, but ... index, any system that relies heavily,on survey data ...
    ... Diagnostic Technologies in Development for Use in ... ... & Johnson Nordic,AB, a Johnson & Johnson company, today announced ... vitro diagnostic (IVD) technologies,for use in Point-of-Care (POC) and near-patient ...
    ... Thousands of Racers and Sponsorship of Survivor Cafe Continues Longstanding ... Community Support By Binson,s, DETROIT, ... the May 31st Susan G. Komen Detroit Race for,the Cure(R) with the ... team., For 26 years, the Komen Race for the Cure Series ...
    Cached Medicine News:Health News:Restoration Industry Association Provides Evacuation Checklist for Residents Impacted by Flooding 2Health News:First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia 2Health News:AHCA Emphasizes Quality Improvement in America's Nursing Homes 2Health News:Johnson & Johnson Nordic AB Acquires Amic 2Health News:Johnson & Johnson Nordic AB Acquires Amic 3Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 2Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 3Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 4
    ... is a widely used screening test for ... precision oriented Dispette branded system is considered ... tube stamp. No other system meets defined ... patient care. Specialized systems are also available ...
    DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
    ... contains 266 amino acids and is variably N-glycosylated. ... estimates of between 43 and 56 kDa. Insulin-like ... with high affinity but do not bind insulin. ... characterized at this time, IGFBP-3 has been shown ...
    ... the detection and semi-quantitation ... Scl-70 antigen in serum ... the diagnosis of autoimmune ... be performed either manually ...
    Medicine Products: